PepGen Inc. (NASDAQ:PEPG – Free Report) – Analysts at Leerink Partnrs upped their Q1 2025 earnings estimates for PepGen in a report issued on Monday, February 24th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings per share of ($0.75) for the quarter, up from their prior estimate of ($0.76). The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. Leerink Partnrs also issued estimates for PepGen’s Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.21) EPS and FY2026 earnings at ($2.93) EPS.

PepGen (NASDAQ:PEPG – Get Free Report) last released its earnings results on Monday, February 24th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.13.

A number of other research analysts have also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of PepGen in a research report on Monday. Bank of America downgraded shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price objective on the stock. in a report on Monday, December 16th. Finally, Wedbush reduced their target price on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, November 8th.

View Our Latest Stock Report on PEPG

PepGen Trading Up 58.8 %

Shares of NASDAQ PEPG opened at $2.43 on Wednesday. The stock has a fifty day simple moving average of $2.38 and a two-hundred day simple moving average of $5.72. PepGen has a 1-year low of $1.16 and a 1-year high of $19.30. The firm has a market cap of $79.21 million, a price-to-earnings ratio of -0.82 and a beta of 1.53.

Institutional Investors Weigh In On PepGen

Several hedge funds and other institutional investors have recently modified their holdings of PEPG. RTW Investments LP bought a new stake in PepGen during the fourth quarter worth about $12,102,000. Janus Henderson Group PLC boosted its stake in shares of PepGen by 331.2% in the 3rd quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock valued at $20,012,000 after purchasing an additional 1,794,641 shares in the last quarter. Suvretta Capital Management LLC grew its holdings in shares of PepGen by 9.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock valued at $14,201,000 after purchasing an additional 140,000 shares during the last quarter. Northern Trust Corp raised its position in PepGen by 5.4% in the 4th quarter. Northern Trust Corp now owns 157,038 shares of the company’s stock worth $595,000 after purchasing an additional 7,984 shares during the period. Finally, Millennium Management LLC lifted its stake in PepGen by 1,033.2% in the fourth quarter. Millennium Management LLC now owns 156,636 shares of the company’s stock worth $594,000 after purchasing an additional 142,814 shares during the last quarter. 58.01% of the stock is currently owned by institutional investors.

About PepGen

(Get Free Report)

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.

Featured Stories

Receive News & Ratings for PepGen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for PepGen and related companies with MarketBeat.com’s FREE daily email newsletter.